Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 38

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 38
---
 the record date. Required Vote

| • |     | Proposal 1—The Merger Agreement Proposal. The affirmative vote, virtually or by proxy, of holders of                                                                                                             
 at least a majority of the outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock entitled to vote on the Merger Agreement Proposal is required to approve the Merger Agreement Proposal. |

| • |     | Proposal 2—The Adjournment Proposal. The affirmative vote, virtually or by proxy, of a majority of                                                                                          
 the votes properly cast by holders of shares of Enfusion Common Stock and Enfusion Class B Common Stock represented at the Special Meeting is required to approve the Adjournment Proposal. |

As of the record date, Enfusion directors and executive officers, as a group, owned and were entitled to vote shares of Enfusion Common Stock and Enfusion Class B Common Stock, or approximately % of the outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock. Enfusion currently expects that these directors and executive officers will vote their shares in favor of approving the Merger Agreement Proposal and the Adjournment Proposal, although none of them are obligated to do so, other than Oleg Movchan with respect to the Merger Agreement Proposal and the Adjournment Proposal. Concurrently with the execution of the Merger Agreement, each of the Significant Stockholders have agreed to vote all of the shares of Enfusion Common Stock and Enfusion Class B Common Stock held by them (representing in the aggregate approximately % of the total outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock as of the record date) in favor of the Merger Agreement Proposal, as described in more detail in the section titled “The Support Agreements.” Enfusion’s Reasons for the Transactions; Recommendations of the Special Committee and Enfusion Board(see page 78) Recommendations of the Special Committee On January 10, 2025, the special committee (the “ Special Committee”) of the Enfusion Board unanimously (i) concluded that the terms and conditions of the Merger Agreement, the Mergers and the other transactions

19

contemplated by the Merger Agreement are advisable, fair to and in the best interests of Enfusion and Enfusion Stockholders, (ii) recommended that the Enfusion Board (a) adopt a
resolution (x) adopting and approving (including for purposes of Section 203 of the DGCL), the Merger Agreement, the Mergers and the other transactions contemplated by the